Navigation Links
Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December
Date:9/17/2009

weight.

Of the placebo patients who completed the trial, 34.9% and 16.1% achieved at least 5% and 10% weight loss, respectively, and the average weight loss was 8.7 pounds, or 3.9%. The top quartile of lorcaserin patients lost 36% more body weight than the top quartile of placebo patients.

For the patients treated with 10 mg of lorcaserin dosed once daily (QD) and completing the 52-week trial according to protocol, 53.1% lost at least 5% of their body weight and 26.3% lost at least 10% of their body weight. The average weight loss in the lorcaserin 10 mg once daily group was 14.3 pounds, or 6.5%. As with the higher dose, all results were highly statistically significant (p<0.0001 compared to placebo).

Intent-to-Treat Last Observation Carried Forward (ITT-LOCF) Results

Measurements of efficacy using ITT-LOCF analysis also showed that lorcaserin met all primary endpoints. This analysis includes all patients who were randomized and returned for at least one weight measurement. Patients treated with 10 mg of lorcaserin once or twice daily achieved highly statistically significant categorical and average weight loss after 12 months:

Lorcaserin 10 mg Twice Daily

  • 47.2% of patients treated with 10 mg of lorcaserin dosed twice daily lost at least 5% of their body weight compared to 25.0% for placebo (p<0.0001). This result satisfies the efficacy benchmark in the most recent FDA draft guidance which provides that a weight-management product can be considered effective if the proportion of patients who lose at least 5% of baseline body weight in the active-product group is at least 35%, is approximately double the proportion in the placebo-treated group, and the difference between groups is statistically significant;
  • 22.6% of patients treated with 10 mg of lorcaserin dosed twice daily lo
    '/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014  El Camino Hospital, a ... care, is utilizing the Leaf Patient Monitoring system to ... and movement of patients susceptible to bed sores. ... month-long, 138-patient study of the system, which showed dramatic ... Turning patients regularly is the one of the most ...
(Date:7/30/2014)... , July 30, 2014  InnoPharma, Inc. today ... 10mg/vial (the generic equivalent of Zyprexa® injection), in Canada.  ... and disturbed behaviors in patients with schizophrenia or bipolar ... generic injectable drug, InnoPharma has entered into an agreement ... Canada will make, use, sell, market and distribute ...
(Date:7/30/2014)... Cynosure, Inc. (NASDAQ: CYNO ... non-invasive and minimally invasive applications, today announced that the Board ... and Chief Financial Officer Timothy W. Baker to ... will continue to serve as CFO and will take the ... Chairman and Chief Executive Officer. "Tim has ...
Breaking Medicine Technology:El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 2El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 3InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2Cynosure Appoints Chief Operating Officer and Chief Financial Officer Timothy W. Baker as President 2
... ST. LOUIS, Dec. 21, 2010 Pepex Biomedical, ... solution for insulin dependent diabetics which will combine ... sufferers worldwide.  The company is developing a complete ... testing of blood glucose levels and insulin delivery, ...
... Reportlinker.com announces that a new market research report ... Cyclohexane: 2010 World Market Outlook And Forecast ... market research features all the important sides of ... focusing on the world market, regional and countries, ...
Cached Medicine Technology:Pepex™ Unveils Development of First All-In-One Blood Glucose Meter 2Reportlinker Adds Cyclohexane: 2010 World Market Outlook And Forecast 2
(Date:7/30/2014)... The family of a Vermont man ... Xarelto lawsuit ( http://www.xareltolawsuitcenter.com/ ) alleging his death ... reports. According to the complaint, which was filed in ... July 25th, the decedent had been taking Xarelto for ... bleed that ultimately led to his death on August ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Hamilton ... opening of its new Carmel office on July 30th. ... will finally be moving to the state-of-the-art suite, located ... and innovative space will allow for one-on-one patient comfort, ... surgery experience. , Dr. Hamilton’s new office-suite will ...
(Date:7/30/2014)... 2014 DRE Medical — a leading ... launch of its Medical Trade Shows & Conventions ... professionals and equipment vendors. , The calendar is a ... the United States and around the world. Hundreds of ... number is always growing. , Information listed on each ...
(Date:7/30/2014)... The Technology Association of Georgia in ... (B&TA), today issued its final call for applications and ... companies have until August 29th 2014 to be considered ... selected by the Excalibur Judging Committee. Companies selected as ... judges for interviewing process. , The TAG Excalibur ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 LTC Consumer, an ... long term care insurance, features an Instant Quote tool on ... and co-founder of LTC Consumer. Quotes are free and unlimited. ... click in only seven areas – including age, gender, and ... screen within seconds (you don’t need to enter any contact ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 3Health News:Hamilton Facial Plastic Surgery Opens New Carmel Office 2Health News:DRE Launches Online Interactive Medical Trade Show Calendar 2Health News:Last Call for TAG 2014 Excalibur Awards Nominations and Applications 2Health News:Last Call for TAG 2014 Excalibur Awards Nominations and Applications 3Health News:LTC Consumer Launches Online Tool for Getting Instant Long Term Care Insurance Estimates 2
... acclaimed as the "gold-standard" amongst researchers for scientific studies. ... on the other, has also questioned the worth of ... complementary and alternative medicine (CAM) practices. Majority of CAM ... cure. , ,The question arises as to whether ...
... Diabetes is the leading cause of end-stage kidney disease ... or a kidney transplant for survival. // ,A ... and the University of Heidelberg has proven that a ... kidney failure or "end-stage renal disease." ,The ...
... are facing one of the worst gastroenteritis epidemics that ... with patients coming// in droves for relief. The infection ... for a few days but seldom endangers life. ... Montreal area have reported the viral outbreak. Dr. Joseph ...
... have been created from blue green algae by scientists with ... on properties and actions of enzymes is also taken into ... possible to produce enough of the promising drugs for use ... the cover of the January issue of the journal ACS ...
... recent studies have shown that the chance of developing it ... the chances of surviving it, also depend on the same ... 50,000 pounds behind a study to be carried out by ... cancer survivors aged above fifty and with a BMI (Body ...
... detect infection of drug resistant forms of HIV even when ... the Duke University Medical Center. ,This new test ... in small amounts contrary to other tests that detect drug-resistant ... bloodstream. ,This new test is expected to be ...
Cached Medicine News:Health News:Is Evidence-based Medicine Enough to Support Additional Research in Alternative Medicine? 2Health News:A Gene Associated With Severe Kidney Failure in Diabetes Found 2Health News:Anti Cancer Drug from Blue Green Algae 2
... Enzyme-linked immunosorbent assay method for ... autoantibodies to myeloperoxidase in human serum. ... can be used as an aid ... and other conditions associated with elevated ...
... of this Enzyme ImmunoAssay (EIA) is as ... immobilised on a 96 well microtiter plate. ... washing, the trapped molecule is covalently linked ... groups. After washing and denaturing treatment, Angiotensin ...
... determination of Ang II is ... the pharmacological effect and efficiency ... angiotensin converting enzyme inhibitors (ACE ... antagonists as well as for ...
Anti-RSV IgA Assay (ELISA)....
Medicine Products: